We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+0.17%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$233M
AUM Growth
+$20M
(+9.4%)
Cap. Flow
+$21.4M
Cap. Flow
% of AUM
9.22%
Top 10 Holdings %
Top 10 Hldgs %
39.53%
Holding
45
New
6
Increased
12
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$8.1M |
| 2 |
AbbVie
ABBV
|
+$6.12M |
| 3 |
Medtronic
MDT
|
+$5.5M |
| 4 |
Humana
HUM
|
+$4.7M |
| 5 |
UnitedHealth
UNH
|
+$4.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revvity
RVTY
|
+$2.8M |
| 2 |
Globus Medical
GMED
|
+$2.8M |
| 3 |
Stryker
SYK
|
+$2.65M |
| 4 |
Johnson & Johnson
JNJ
|
+$2.65M |
| 5 |
Moderna
MRNA
|
+$2.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Elevance Health
ELV
$86.6B
| $4.85M | 2.08% |
10,543
+2,543
| +32% | +$1.21M |
|
27
Vertex Pharmaceuticals
VRTX
$133B
| $4.73M | 2.03% |
15,000
| – | – |
|
28
Waters Corp
WAT
$40.9B
| $4.64M | 2% |
15,000
| – | – |
|
29
Abbott
ABT
$192B
| $4.56M | 1.96% |
45,000
| – | – |
|
30
IQVIA
IQV
$39.8B
| $3.98M | 1.71% |
20,000
+5,000
| +33% | +$1.07M |
|
31
Cigna
CI
$73.3B
| $3.83M | 1.65% |
15,000
-5,000
| -25% | -$1.46M |
|
32
Becton Dickinson
BDX
$50B
| $3.71M | 1.6% |
+15,000
| New | +$3.67M |
|
|
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.24M | 1.39% |
16,000
+3,000
| +23% | +$481K |
|
34
Icon
ICLR
$12.9B
| $3.2M | 1.38% |
15,000
| – | – |
|
35
Encompass Health
EHC
$12.3B
| $2.98M | 1.28% |
55,000
-30,000
| -35% | -$1.75M |
|
|
SEM
36
DELISTED
Select Medical
SEM
| $2.79M | 1.2% |
200,147
+14,547
| +8% | +$214K |
|
37
Biogen
BIIB
$30.9B
| $2.78M | 1.2% |
10,000
| – | – |
|
38
Option Care Health
OPCH
$3.57B
| $2.54M | 1.09% |
80,000
-50,000
| -38% | -$1.5M |
|
39
Sarepta Therapeutics
SRPT
$1.94B
| $1.79M | 0.77% |
+13,000
| New | +$1.69M |
|
40
Alnylam Pharmaceuticals
ALNY
$30B
| $1.5M | 0.65% |
+7,500
| New | +$1.58M |
|
41
BioNTech
BNTX
$23.3B
| – | – |
-13,000
| Closed | -$1.95M |
|
|
42
Globus Medical
GMED
$11.5B
| – | – |
-37,745
| Closed | -$2.8M |
|
|
43
Johnson & Johnson
JNJ
$629B
| – | – |
-15,000
| Closed | -$2.65M |
|
|
44
Moderna
MRNA
$25.4B
| – | – |
-13,000
| Closed | -$2.33M |
|
|
45
Revvity
RVTY
$13.2B
| – | – |
-20,000
| Closed | -$2.8M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q1 2023 Portfolio in Review
As of Q1 2023, Sivik Global Healthcare held 45 positions worth $233M, up 9.4% from $213M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Sivik Global Healthcare deployed $21.4M of net new capital in Q1 2023, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 75,000 shares worth $7.98M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier.
On the sell side, the largest reduction was Stryker, an estimated $2.65M trimmed.
- Sivik Global Healthcare's largest Q1 2023 buy was Merck: 75,000 shares worth $7.98M.
- Sivik Global Healthcare added most to Humana in Q1 2023, an estimated $4.7M increase.
- Sivik Global Healthcare's biggest Q1 2023 reduction was Stryker, cutting an estimated $2.65M.
- Sivik Global Healthcare fully exited Revvity in Q1 2023, selling an estimated $2.8M.
- Sivik Global Healthcare's ten largest holdings make up 40% of its $233M portfolio in Q1 2023.
- Sivik Global Healthcare opened 6 new positions and closed 5 in Q1 2023.
- Sivik Global Healthcare's portfolio value rose 9.4% quarter-over-quarter to $233M.
Based on Sivik Global Healthcare's 13F filing for Q1 2023, filed 8 May 2023.